In an ongoing adaptive platform trial, the effect of new initiation of an RAS inhibitor (either an ACE inhibitor or an angiotensin receptor blocker [ARB]) on the composite outcome of hospital survival and organ support provision through 21 days was evaluated in patients hospitalized with COVID-19 pneumonia.
Read article